The DOI matches its Crossref record; 247 of the 247 references it cites were found in a registry or an index.
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888
Allelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
Lachman, H. M., Papolos, D. F., Saito, T., Yu, Y.-M., Szumlanski, C. L., & Weinshilboum, R. M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00007 · Cited by 1,788
Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform
Walther, D. J., Peter, J.-U., Bashammakh, S., Hörtnagl, H., Voits, M., Fink, H., & Bader, M. (2003) · Science · doi:10.1126/science.1078197 · Cited by 1,570
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
A functional polymorphism in the monoamine oxidase A gene promoter
Sabol, S. Z., Hu, S., & Hamer, D. (1998) · Human Genetics · doi:10.1007/s004390050816 · Cited by 1,079
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
Self-citationSummary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Pohjalainen, T., Rinne, J. O., Någren, K., Lehikoinen, P., Anttila, K., Syvälahti, E. K. G., & Hietala, J. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000350 · Cited by 673
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Smeraldi, E., Zanardi, R., Benedetti, F., Bella, D. D., Perez, J., & Catalano, M. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000425 · Cited by 614
Genes for schizophrenia? Recent findings and their pathophysiological implications
Harrison, P. J., & Owen, M. J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12379-3 · Cited by 597
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
Bertilsson, L., Dahl, M., Dalén, P., & Al‐Shurbaji, A. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01548.x · Cited by 579
Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes
Yang, P., Kanki, H., Drolet, B., Yang, T., Wei, J., Viswanathan, P. C., Hohnloser, S. H., Shimizu, W., Schwartz, P. J., Stanton, M., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014448.19052.4c · Cited by 554
INCREASED SEROTONIN-2 BINDING SITES IN FRONTAL CORTEX OF SUICIDE VICTIMS
Stanley, M., & Mann, J. J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92590-4 · Cited by 529
Manji, H. K., Quiroz, J. A., Sporn, J., Payne, J. L., Denicoff, K., A. Gray, N., Zarate, C. A., & Charney, D. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00117-3 · Cited by 505
Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy
Song, F., Khan, K. S., Dinnes, J., & Sutton, A. J. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.88 · Cited by 484
Sánchez, C., & Hyttel, J. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006986824213 · Cited by 429
Kirchheiner, J., Brøsen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjöqvist, F., Spina, E., & Brockmöller, J. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.00299.x · Cited by 422
Self-citationPollock, B. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00132-9 · Cited by 415
Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism
Reynolds, G. P., Zhang, Z.-J., & Zhang, X.-B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08913-4 · Cited by 412
Serotonin transporter gene polymorphism and antidepressant response
Kim, D. K., Lim, S.-W., Lee, S., Sohn, S. E., Kim, S., Hahn, C. G., & Carroll, B. J. (2000) · NeuroReport · doi:10.1097/00001756-200001170-00042 · Cited by 398
MacKenzie, A., & Quinn, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15251 · Cited by 374
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
Pharmacogenetic prediction of clozapine response
Arranz, M., Munro, J., Birkett, J., Bolonna, A., Mancama, D., Sodhi, M., Lesch, K., Meyer, J., Sham, P., Collier, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02221-2 · Cited by 347
Nakajima, M., Yokoi, T., Mizutani, M., Kinoshitah, M., Funayama, M., & Kamataki, T. (1999) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022352 · Cited by 346
Bauer, M., Whybrow, P. C., Angst, J., Versiani, M., Möller, H.-J., & WFSBP Task Force on Treatment Guide (2002) · The World Journal of Biological Psychiatry · doi:10.3109/15622970209150599 · Cited by 346
Self-citationAssociation between clozapine response and allelic variation in 5-HT2A receptor gene
Arranz, M. J., Collier, D. A., Sodhi, M., Ball, D., Roberts, G. W., Sham, P., Kerwin, R., Price, J., & Roberts, G. W. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92168-0 · Cited by 333
Jeppesen, U., Gram, L. F., Vistisen, K., Loft, S., Poulsen, H. E., & Brøsen, K. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050163 · Cited by 321
Clinical Pharmacokinetics of Mirtazapine
Timmer, C. J., Ad Sitsen, J. M., & Delbressine, L. P. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038060-00001 · Cited by 319
Huang, M.-L., Peer, A. V., Woestenborghs, R., De Coster, R., Heykants, J., Jansen, A. A. I., Zylicz, Z., Visscher, H. W., & Jonkman, J. H. G. (1993) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1993.146 · Cited by 316
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J., & Schuetz, E. G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00006 · Cited by 316
Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA
Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1108 · Cited by 314
Self-citationZanardi, R., Benedetti, F., Di Bella, D., Catalano, M., & Smeraldi, E. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200002000-00021 · Cited by 308
Kunugi, H., Hattori, M., Kato, T., Tatsumi, M., Sakai, T., Sasaki, T., Hirose, T., & Nanko, S. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000334 · Cited by 305
Metabolism of Tricyclic Antidepressants
Rudorfer, M. V., & Potter, W. Z. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006949816036 · Cited by 296
10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes*
Dalén, P., Dahl, M.-L., Ruiz, M. L. B., Nordin, J., & Bertilsson, L. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90040-6 · Cited by 285
Pharmacogenetics of Antidepressant Medication Intolerance
Murphy, G. M., Kremer, C., Rodrigues, H. E., & Schatzberg, A. F. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.10.1830 · Cited by 283
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6
Kirchheiner, J., Klein, C., Meineke, I., Sasse, J., Zanger, U. M., M??rdter, T. E., Roots, I., & Brockm??ller, J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00005 · Cited by 249
Self-citationYu, Y. W.-Y., Tsai, S.-J., Chen, T.-J., Lin, C.-H., & Hong, C.-J. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001141 · Cited by 246
Entsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Lerer, B. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00293-2 · Cited by 241
Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
Steen, V. M., Løvlie, R., MacEwan, T., & McCreadie, R. G. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000249 · Cited by 239
Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoin
Kidd, R. S., Curry, T. B., Gallagher, S., Edeki, T., Blaisdell, J., & Goldstein, J. A. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00008 · Cited by 236
The Effect of Paroxetine on 5-HT2A Receptors in Depression: An [18F]Setoperone PET Imaging Study
Meyer, J. H., Kapur, S., Eisfeld, B., Brown, G. M., Houle, S., DaSilva, J., Wilson, A. A., Rafi-Tari, S., Mayberg, H. S., & Kennedy, S. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.1.78 · Cited by 231
Venlafaxine oxidation in vitro is catalysed by CYP2D6
OTTON, S. V., BALL, S. E., CHEUNG, S. W., INABA, T., RUDOLPH, R. L., & SELLERS, E. M. (1996) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1996.tb00173.x · Cited by 227
Chou, W. H., Yan, F.-X., de Leon, J., Barnhill, J., Rogers, T., Cronin, M., Pho, M., Xiao, V., Ryder, T. B., Liu, W. W., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00019 · Cited by 226
Yoshida, K., Ito, K., Sato, K., Takahashi, H., Kamata, M., Higuchi, H., Shimizu, T., Itoh, K., Inoue, K., Tezuka, T., et al. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00287-1 · Cited by 226
Psychotropic Drugs, Cardiac Arrhythmia, and Sudden Death
Witchel, H. J., Hancox, J. C., & Nutt, D. J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00010 · Cited by 221
Arranz, M. J., Munro, J., Owen, M. J., Spurlock, G., Sham, P. C., Zhao, J., Kirov, G., Collier, D. A., & Kerwin, R. W. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000348 · Cited by 220
Zanardi, R., Serretti, A., Rossini, D., Franchini, L., Cusin, C., Lattuada, E., Dotoli, D., & Smeraldi, E. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01118-0 · Cited by 219
Tsai, S., Cheng, C., Yu, Y. W., Chen, T., & Hong, C. (2003) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20026 · Cited by 214
Sindrup, S. H., Brøsen, K., Hansen, M. G. J., Aaes-Jørgensen, T., Overø, K. F., & Gram, L. F. (1993) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199302000-00002 · Cited by 213
The relationship between paroxetine and the sparteine oxidation polymorphism
Sindrup, S. H., Brøsen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., Tasker, T. C. G., et al. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.23 · Cited by 205
Brockmöller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C., Müller‐Oerlinghausen, B., & Roots, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127494 · Cited by 204
Self-citationReynolds, G. P., Zhang, Z., & Zhang, X. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.677 · Cited by 198
Zill, P., Baghai, T. C., Zwanzger, P., Schüle, C., Minov, C., Riedel, M., Neumeier, K., Rupprecht, R., & Bondy, B. (2000) · NeuroReport · doi:10.1097/00001756-200006260-00018 · Cited by 197
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers
Skinner, M. H., Kuan, H., Pan, A., Sathirakul, K., Knadler, M. P., Gonzales, C. R., Yeo, K. P., Reddy, S., Lim, M., Ayan‐Oshodi, M., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.28 · Cited by 195
Rausch, J. L., Johnson, M. E., Fei, Y.-J., Li, J. Q., Shendarkar, N., Mac Hobby, H., Ganapathy, V., & Leibach, F. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01283-5 · Cited by 193
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.-U., Schwab, M., & Zanger, U. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00001 · Cited by 189
Minov, C., Baghai, T. C., Schüle, C., Zwanzger, P., Schwarz, M. J., Zill, P., Rupprecht, R., & Bondy, B. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01704-9 · Cited by 189
Association between clozapine response and allelic variation in the 5-HT2C receptor gene
Sodhi, M. S., Arranz, M. J., Curtis, D., Ball, D. M., Sham, P., Roberts, G. W., Price, J., Collier, D. A., & Kerwin, R. W. (1995) · NeuroReport · doi:10.1097/00001756-199512000-00041 · Cited by 188
Xie, H.-G., Stein, C. M., Kim, R. B., Wilkinson, G. R., Flockhart, D. A., & Wood, A. J. J. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00001 · Cited by 181
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment
Perlis, R. H., Mischoulon, D., Smoller, J. W., Wan, Y.-J. Y., Lamon-Fava, S., Lin, K.-M., Rosenbaum, J. F., & Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00424-4 · Cited by 177
Carrillo, J. A., Herráiz, A. G., Ramos, S. I., Gervasini, G., Vizcaíno, S., & Benítez, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00003 · Cited by 177
Polymorphisms in dopamine receptors: what do they tell us?
Hung Choy Wong, A., Buckle, C. E., & Van Tol, H. H. M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00815-3 · Cited by 176
Caccia, S. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834040-00002 · Cited by 175
Venkatakrishnan, K., Greenblatt, D. J., Moltke, L. L., Schmider, J., Harmatz, J. S., & Shader, R. I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04399.x · Cited by 175
Sachse, C., Bhambra, U., Smith, G., Lightfoot, T. J., Barrett, J. H., Scollay, J., Garner, R. C., Boobis, A. R., Wolf, C. R., Gooderham, N. J., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01733.x · Cited by 174
Krebs, M. O., Guillin, O., Bourdel, M. C., Schwartz, J. C., Olie, J. P., Poirier, M. F., & Sokoloff, P. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000749 · Cited by 173
Basile, V. S., Özdemir, V, Masellis, M., Walker, M. L., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Alva, G., Kalow, W., Macciardi, F. M., et al. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000736 · Cited by 168
Benedetti, F., Serretti, A., Colombo, C., Campori, E., Barbini, B., di Bella, D., & Smeraldi, E. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1450 · Cited by 167
D2 dopamine receptor polymorphism and brain regional glucose metabolism
Noble, E. P., Gottschalk, L. A., Fallon, J. H., Ritchie, T. L., & Wu, J. C. (1997) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19970418)74:2<162::aid-ajmg9>3.0.co;2-w · Cited by 166
Basile, V (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00114-6 · Cited by 164
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings
Dahl-Puustinen, M.-L., Lidén, A., Alm, C., Nordin, C., & Bertilsson, L. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.109 · Cited by 164
Dahl, M.-L. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00001 · Cited by 163
Serretti, A., Zanardi, R., Rossini, D., Cusin, C., Lilli, R., & Smeraldi, E. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000876 · Cited by 162
Mundo, E., Walker, M., Cate, T., Macciardi, F., & Kennedy, J. L. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.539 · Cited by 161
Yu, Y. W. ‐., Chen, T., Hong, C., Chen, H.-M., & Tsai, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300172 · Cited by 159
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu, A., Idle, J. R., Byrd, L. G., Krausz, K. W., Kupfer, A., & Gonzalez, F. J. (2003) · PubMed · doi:10.1097/01.fpc.0000054066.98065.7b · Cited by 158
von Bahr, C., Movin, G., Nordin, C., Lidén, A., Hammarlund-Udenaes, M., Hedberg, A., Ring, H., & Sjöqvist, F. (1991) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1991.22 · Cited by 158
Sindrup, S. H., Brøsen, K., & Gram, L. F. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.24 · Cited by 156
Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia
Segman, R. H., Heresco‐Levy, U., Finkel, B., Goltser‐Dubner, T., Shalem, R., Schlafman, M., Dorevitch, A., Yakir, A., Greenberg, D. A., Lerner, A., et al. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000842 · Cited by 155
Segman, R. H., Neeman, T., Heresco‐Levy, U., Finkel, B., Karagichev, L., Schlafman, M., Dorevitch, A., Yakir, A., Lerner, A., Shelevoy, A., et al. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000511 · Cited by 153
Dostert, P., Benedetti, M. S., & Poggesi, I. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00417-3 · Cited by 150
Shaikh, S., Collier, D. A., Sham, P. C., Ball, D., Aitchison, K. J., Vallada, H., Kerwin, R. W., Smith, I., & Gill, M. (1996) · Human Genetics · doi:10.1007/bf02346178 · Cited by 150
Chen, S., Chou, W.-H., Blouin, R. A., Mao, Z. L., Humphries, L. L., Meek, Q. C., Neill, J. R., Martin, W. L., Hays, L. R., & Wedlund, P. J. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90148-4 · Cited by 149
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Venlafaxine Serum Levels and CYP2D6 Genotype
Veefkind, A. H., Haffmans, P. M. J., & Hoencamp, E. (2000) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200004000-00011 · Cited by 146
Yokota, H., Tamura, S., Furuya, H., Kimura, S., Watanabe, M., Kanazawa, I., Kondo, I., & Gonzalez, F. J. (1993) · Pharmacogenetics · doi:10.1097/00008571-199310000-00005 · Cited by 144
Hong, C., Yu, Y. W. ‐., Lin, C., & Tsai, S. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00828-0 · Cited by 144
Skjelbo, E., Brøsen, K., Hallas, J., & Gram, L. F. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.4 · Cited by 144
Alfaro, C. L., Lam, Y. W. F., Simpson, J., & Ereshefsky, L. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004000108 · Cited by 142
Dopamine D4 receptor subtypes and response to clozapine
Shaikh, S., Collier, D., Kerwin, R. W., Pilowsky, L. S., Gill, M., Xu, W.-M., & Thornton, A. (1993) · The Lancet · doi:10.1016/0140-6736(93)92594-j · Cited by 138
Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine
Arranz, M. J., Collier, D. A., Munro, J., Sham, P. C., Kirov, G., Sodhi, M., Roberts, G. W., Price, J., & Kerwin, R. W. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)13094-9 · Cited by 136
Polymorphic debrisoquin hydroxylation in 757 Swedish subjects
Steiner, E., Bertilsson, L., Säwe, J., Bertling, I., & Sjöqvist, F. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.176 · Cited by 133
−759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain
Tsai, S., Hong, C., Yu, Y. W. ‐., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11705-3 · Cited by 131
Manganese Superoxide Dismutase Gene Polymorphism and Schizophrenia Relation to Tardive Dyskinesia
Hori, H. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00156-6 · Cited by 130
Malhotra, A. K., Goldman, D. A., Ozaki, N., et al. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.8.1092 · Cited by 129
Desta, Z., Kerbusch, T., & Flockhart, D. A. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70117-7 · Cited by 129
Tryptophan hydroxylase gene associated with paroxetine antidepressant activity
Serretti, A., Zanardi, R., Cusin, C., Rossini, D., Lorenzi, C., & Smeraldi, E. (2001) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00113-4 · Cited by 127
Serotonin-6 receptor variant (C267T) and clinical response to clozapine
Yu, Y. W. ‐., Tsai, S., Lin, C., Hsu, C., Yang, K., & Hong, C. (1999) · Neuroreport · doi:10.1097/00001756-199904260-00014 · Cited by 126
Jönsson, E. G., Goldman, D. A., Spurlock, G., Gustavsson, P. J., Nielsen, D. A., Linnoila, M., Owen, M. J., & Sedvall, G. C. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02922258 · Cited by 125
Carrillo, J. A., Dahl, M., Svensson, J., Alm, C., Rodríguez, I., & Bertilsson, L. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90134-4 · Cited by 122
Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor
Rietschel, M., Naber, D., Fimmers, R., et al. (1997) · Neuroreport · doi:10.1097/00001756-199705260-00040 · Cited by 119
Nöthen, M. M., Cichon, S., Hemmer, S., Hebebrand, J., Remschmidt, H., Lehmkuhl, G., Poustka, F., Schmidt, M., Catalano, M., Fimmers, R., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.12.2207 · Cited by 119
Serum Concentrations and Side Effects in Psychiatric Patients During Risperidone Therapy
Olesen, O. V., Licht, R. W., Thomsen, E., Bruun, T., Viftrup, J. E., & Línnet, K. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199808000-00004 · Cited by 119
PCR-based genotyping for duplicated and deleted CYP2D6 genes
Johansson, I., Lundqvist, E., Dahl, M., & Ingelman‐Sundberg, M. (1996) · Pharmacogenetics · doi:10.1097/00008571-199608000-00008 · Cited by 114
Dahl, M.-L., LLerena, A., Bondesson, U., Lindström, L., & Bertilsson, L. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04242.x · Cited by 114
D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine
Potkin, S. G., Basile, V. S., Jin, Y., Masellis, M., Badri, F., Keator, D., Wu, J. C., Alva, G., Carreon, D., Bunney, W. E., et al. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001191 · Cited by 113
The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin*
Hamelin, B. A., Turgeon, J., Vallée, F., Bélanger, P.-M., Paquet, F., & LeBel, M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90147-2 · Cited by 113
Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine
Rao, P. A. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110072009 · Cited by 112
Genetic variation of the 5-HT2A receptor and response to clozapine
Nöthen, M. M., Rietschel, M., Erdmann, J., Oberländer, H., Möller, H., Naber, D., Propping, P., Burnet, P. W. J., & Harrison, P. J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92756-5 · Cited by 111
Cusin, C., Serretti, A., Zanardi, R., Lattuada, E., Rossini, D., Lilli, R., Lorenzi, C., & Smeraldi, E. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145701002711 · Cited by 110
Andreassen, O. A., MacEwan, T., Gulbrandsen, A.-K., McCreadie, R. G., & Steen, V. M. (1997) · Psychopharmacology · doi:10.1007/s002130050281 · Cited by 107
Rietschel, M., Naber, D., Oberländer, H., Holzbach, R., Fimmers, R., Eggermann, K., Möller, H. J., Propping, P., & Nöthen, M. M. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00090-5 · Cited by 103
Spina, E., Gitto, C., Avenoso, A., Campo, G. M., Caputi, A. P., & Perucca, E. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050220 · Cited by 103
Br�sen, K., Klysner, R., Gram, L. F., Otton, S. V., Bech, P., & Bertilsson, L. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00608215 · Cited by 102
Løvlie, R., Daly, A. K., Matre, G. E., Molven, A., & Steen, V. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00006 · Cited by 101
Jerling, M., Dahl, M., Åberg‐Wistedt, A., Liljenberg, B., Landell, N.-E., Bertilsson, L., & Sjöqvist, F. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90111-3 · Cited by 101
Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype
Brøsen, K., Otton, S. V., & Gram, L. F. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.221 · Cited by 100
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
FJORDSIDE, L., Jeppesen, U., Eap, C. B., Powell, K., Baumann, P., & Brossen, K. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00008 · Cited by 100
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*
Gram, L. F., Guentert, T. W., Grange, S., Vistisen, K. K., & Brøsen, K. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90230-9 · Cited by 100
Özdemir, V., KALOW, W., Okey, A. B., Lam, M. S. M., Albers, L. J., Reist, C., Fourie, J., Posner, P., Collins, E. J., & Roy, R. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00011 · Cited by 99
Chen, C.-H., Wei, F., Koong, F., & Hsiao, K. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00543-4 · Cited by 99
Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers
Fukuda, T., Yamamoto, I., Nishida, Y., Zhou, Q., Ohno, M., Takada, K., & Azuma, J. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00913.x · Cited by 98
Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene
Jönsson, E. G., Lannfelt, L., Sokoloff, P., Schwartz, J., & Sedvall, G. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03384.x · Cited by 97
Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response
Birkett, J., Arranz, M. J., Munro, J., Osbourn, S., Kerwin, R. W., & Collier, D. A. (2000) · Neuroreport · doi:10.1097/00001756-200006260-00042 · Cited by 96
LLerena, A., Dahl, M., Ekqvist, B., & Bertilsson, L. (1992) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199206000-00014 · Cited by 96
Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype
Armstrong, M., Daly, A. K., Blennerhassett, R. C., Ferrier, N., & Idle, J. R. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.170.1.23 · Cited by 96
Kaiser, R., Tremblay, P.-B., Schmider, J., Henneken, M., Dettling, M., Müller-Oerlinghausen, B., Uebelhack, R., Roots, I., & Brockmöller, J. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000821 · Cited by 95
Self-citationRole of CYP2D6 in the stereoselective disposition of venlafaxine in humans.
Eap, C. B., Lessard, E., Baumann, P., Brawand-Amey, M., Yessine, M., O’Hara, G. E., & Turgeon, J. (2003) · Pharmacogenetics · doi:10.1097/00008571-200301000-00006 · Cited by 95
New approaches to managing difficult-to-treat depressions.
Thase, M. E. (2003) · PubMed · Cited by 94
Alfaro, C. L., Lam, Y. W. F., Simpson, J., & Ereshefsky, L. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199904000-00011 · Cited by 94
Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive Dyskinesia
Arthur, H., Dahl, M., Siwers, B., & Sjöqvist, F. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199506000-00010 · Cited by 94
Kaiser, R., Tremblay, P.-B., Klufmöller, F., Roots, I., & Brockmöller, J. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001054 · Cited by 93
Self-citationYue, Q., Zhong, Z., Tybring, G., Dalén, P., Dahl, M., Bertilsson, L., & Sjöqvist, F. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90069-8 · Cited by 91
Yoshida, K., Naito, S., Takahashi, H., Sato, K., Ito, K., Kamata, M., Higuchi, H., Shimizu, T., Itoh, K., Inoue, K., et al. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00267-1 · Cited by 91
Nielsen, K. K., Brøsen, K., Hansen, M. G. J., & Gram, L. F. (1994) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1994.65 · Cited by 91
High and variable frequencies of CYP2C19 mutations
Kaneko, A., Lum, J. K., Yaviong, J., et al. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00005 · Cited by 90
SSRIs antidepressant activity is influenced by Gβ3 variants
Serretti, A. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)00154-2 · Cited by 90
Christensen, M., Tybring, G., Mihara, K., Yasui‐Furokori, N., Carrillo, J. A., Ramos, S., Andersson, K., Dahl, M., & Bertilsson, L. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121788 · Cited by 90
Joober, R., Benkelfat, C., Lal, S., Bloom, D., Labelle, A., Lalonde, P., Turecki, G., Rozen, R. R., & Rouleau, G. A. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000724 · Cited by 89
Laine, K., Tybring, G., Härtter, S., et al. (2001) · PubMed · Cited by 89
Masellis, M., Basile, V. S., Meltzer, H. Y., Lieberman, J. A., Sevy, S. M., Goldman, D. A., Hamblin, M. W., Macciardi, F. M., & Kennedy, J. L. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00016-5 · Cited by 89
Ito, K., Yoshida, K., Sato, K., Takahashi, H., Kamata, M., Higuchi, H., Shimizu, T., Itoh, K., Inoue, K., Tezuka, T., et al. (2002) · Psychiatry Research · doi:10.1016/s0165-1781(02)00141-5 · Cited by 87
Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine
Whale, R., Quested, D. J., Laver, D., Harrison, P. J., & Cowen, P. J. (2000) · Psychopharmacology · doi:10.1007/s002130000432 · Cited by 86
Reist, C., Mazzanti, C. M., Vu, R., Tran, D., & Goldman, D. A. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1360 · Cited by 86
C677T polymorphism in methylenetetrahydrofolate reductase gene and psychoses
Kunugi, H., Fukuda, R., Hattori, M., Kato, T., Tatsumi, M., Sakai, T., Hirose, T., & Nanko, S. (1998) · Molecular Psychiatry · doi:10.1038/sj.mp.4000390 · Cited by 85
Lam, Y. W. F., Gaedigk, A., Ereshefsky, L., Alfaro, C. L., & Simpson, J. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.12.1001.33603 · Cited by 84
The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain
Maj, J., Bijak, M., Dziedzicka‐Wasylewska, M., Rogoż, R., Rogóż, Z., Skuza, G., & Tokarski, T. (1996) · Psychopharmacology · doi:10.1007/bf02805977 · Cited by 81
Kaiser, R., Könneker, M., Henneken, M., Dettling, M., Müller-Oerlinghausen, B., Roots, I., & Brockmöller, J. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000729 · Cited by 81
Self-citationAmitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers
Mellström, B., Säwe, J., Bertilsson, L., & Sjöqvist, F. (1986) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1986.56 · Cited by 81
Polymorphisms of the dopamine D 4 receptor and response to antipsychotic drugs
Cohen, B. M., Ennulat, D. J., Centorrino, F., Matthysse, S., Konieczna, H., Chu, H.-M., & Cherkerzian, S. (1999) · Psychopharmacology · doi:10.1007/s002130050799 · Cited by 80
Suzuki, A., Kondo, T., Otani, K., Mihara, K., Yasui-Furukori, N., Sano, A., Koshiro, K., & Kaneko, S. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1714 · Cited by 80
Roh, H., Chung, J., Oh, D.-Y., Park, C., Svensson, J., Dahl, M., & Bertilsson, L. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01437.x · Cited by 78
Sato, K., Yoshida, K., Takahashi, H., Ito, K., Kamata, M., Higuchi, H., Shimizu, T., Itoh, K., Inoue, K., Tezuka, T., et al. (2002) · Neuropsychobiology · doi:10.1159/000066394 · Cited by 78
In Vitro and In Vivo Studies on the Disposition of Mirtazapine in Humans
Dahl, M., Voortman, G., Alm, C., Elwin, C., Delbressine, L. P. C., Vos, R. M. E., Bogaards, J. J. P., & Bertilsson, L. (1997) · Clinical Drug Investigation · doi:10.2165/00044011-199713010-00005 · Cited by 77
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
Scordo, M. G., Spina, E., Romeo, P., Dahl, M. L., Bertilsson, L., Johansson, I., & Sjöqvist, F. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000222 · Cited by 76
Dahl, M. L., Bertilsson, L., & Nordin, C. (1996) · Psychopharmacology · doi:10.1007/bf02246640 · Cited by 75
Mihara, K., SUZUKI, A., Kondo, T., YASUI, N., Furukori, H., Nagashima, U., Otani, K., Kaneko, S., & INOUE, Y. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70108-6 · Cited by 75
Zhang, Z.-J., Zhang, X.-B., Sha, W.-W., Zhang, X.-B., & Reynolds, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001052 · Cited by 75
Tsai, S., Hong, C., Yu, Y. W. ‐., Lin, C., Song, H., Lai, H., & Yang, K. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00170-x · Cited by 75
Baghai, T. C., Schüle, C., Zwanzger, P., Minov, C., Schwarz, M., Jonge, S. D., Rupprecht, R., & Bondy, B. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000857 · Cited by 75
Bondy, B., Baghai, T. C., Zill, P., Bottlender, R., Jaeger, M., Minov, C., Schüle, C., Zwanzger, P., Rupprecht, R., & Engel, R. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001149 · Cited by 75
Biotransformation of Post-Clozapine Antipsychotics: Pharmacological Implications
Caccia, S. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038050-00002 · Cited by 74
Kohn, Y., Ebstein, R. P., Heresco‐Levy, U., Shapira, B., Nemanov, L., Gritsenko, I., Avnon, M., & Lerer, B. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00380-x · Cited by 74
5HT2a receptor T102C polymorphism and schizophrenia
Clifford, C., Nunez, D. R., Malhotra, A. K., Goldman, D. A., Buchanan, R., Breier, A. F., Pickar, D., Jönsson, E. G., Nöthen, M. M., Bunzel, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91650-5 · Cited by 72
Cravchik, A., Sibley, D. R., & Gejman, P. V. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00003 · Cited by 70
Suzuki, A., Otani, K., Mihara, K., Yasui, N., Kaneko, S., Inoue, Y., & Hayashi, K. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00013 · Cited by 69
Genetic variants of the serotonin system and weight change during clozapine treatment
Hong, C., Lin, C., Yu, Y. W. ‐., Yang, K., & Tsai, S. (2001) · Pharmacogenetics · doi:10.1097/00008571-200104000-00010 · Cited by 69
Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients
Roh, H., Kim, C. E., Chung, W., Park, C., Svensson, J., & Bertilsson, L. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100372 · Cited by 67
Hawi, Z., Straub, R. E., O’Neill, F. A., Kendler, K. S., Walsh, D., & Gill, M. (1998) · Psychiatry Research · doi:10.1016/s0165-1781(98)00076-6 · Cited by 67
Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms
Spigset, O., Granberg, K., Hägg, S., Norström, Å., & Dahlqvist, R. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050261 · Cited by 66
RYBAKOWSKI, J. K., Borkowska, A., Czerski, P. M., & Hauser, J. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000927 · Cited by 66
Dahl, M. L., Ekqvist, B., Widén, J., & Bertilsson, L. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb01428.x · Cited by 66
Schulze, T. G., Schumacher, J. H., Müller, D. J., Krauß, H., Alfter, D., Maroldt, A., Ahle, G., Maroldt, A., y Fernández, A. N., Weber, T., et al. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1472 · Cited by 66
Effectiveness of antidepressants: comparative remission rates.
Thase, M. E. (2003) · PubMed · Cited by 65
No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response
Bolonna, A. A., Arranz, M. J., Munro, J., Osborne, S., Petouni, M., Martínez, M. J., & Kerwin, R. W. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)01000-9 · Cited by 65
Shaikh, S., Collier, D. A., Sham, P. C., Pilowsky, L. S., Sharma, T., Lin, L.-Y., Crocq, M. A., Gill, M., & Kerwin, R. W. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320600611 · Cited by 65
Mihara, K., Kondo, T., Suzuki, A., Yasui‐Furukori, N., Ono, S., Sano, A., Koshiro, K., Otani, K., & Kaneko, S. (2002) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.10025 · Cited by 65
Interaction of the ACE D Allele and the GNB3 825T Allele in Myocardial Infarction
Naber, C. K., Hüsing, J., WOLFHARD, U. F., Erbel, R. M., & Siffert, W. (2000) · Hypertension · doi:10.1161/01.hyp.36.6.986 · Cited by 64
Hori, H., Ohmori, O., Shinkai, T., Kojima, H., & Nakamura, J. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.10045 · Cited by 64
Línnet, K., & Wiborg, O. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90165-4 · Cited by 64
Tsai, S., Wang, Y.-C., Yu, W., Lin, C., Yang, K., & Hong, C. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(00)00127-4 · Cited by 62
Eap, C. B., Bondolfi, G., ZULLINO, D. F., Savary, L., Powell-Golay, K., Kosel, M., & Baumann, P. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200106000-00013 · Cited by 62
Shimoda, K., Someya, T., Yokono, A., Morita, S., Hirokane, G., Takahashi, S., & Okawa, M. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00007 · Cited by 61
Baumann, P., Jonzier-Perey, M., Koeb, L., et al. (1986) · International Clinical Psychopharmacology · doi:10.1097/00004850-198604000-00002 · Cited by 60
Morita, S., Shimoda, K., Someya, T., Yoshimura, Y., Kamijima, K., & Kato, N. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200004000-00005 · Cited by 60
Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.
Pollock, B. G., Mulsant, B. H., Sweet, R. A., Rosen, J., Altieri, L. P., & Perel, J. M. (1995) · PubMed · Cited by 60
Clozapine-induced hypersalivation and the alpha2 adrenoceptor
Corrigan, F. M., Macdonald, S., & Reynolds, G. P. (1995) · The British Journal of Psychiatry · doi:10.1192/bjp.167.3.412a · Cited by 58
High and variable frequencies of CYP2C19 mutations
Kaneko, A., Lum, J. K., Yaviong, J., Takahashi, N., Ishizaki, T., Bertilsson, L., Kobayakawa, T., & Björkman, A. (1999) · Pharmacogenetics and Genomics · doi:10.1097/01213011-199910000-00005 · Cited by 58
Wu, W.-H., Huo, S.-J., Cheng, C.-Y., Hong, C., & Tsai, S. (2001) · Neuropsychobiology · doi:10.1159/000054938 · Cited by 57
Eap, C. B., Guentert, T. W., Schäublin-Loidl, M., et al. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80010-5 · Cited by 57
Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics
Kirchheiner, J., Müller, G., Meineke, I., Wernecke, K., Roots, I., & Brockmöller, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088909.24613.92 · Cited by 57
Self-citation
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
“The area has been extensively reviewed (Kirchheiner et al., 2004; Bertilsson, 2007; Crisafulli et al., 2011; Stingl et al., 2012).”
BackgroundConsensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder
(2008) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.149114 · Cited by 1,028
Metadata
- Authors
- Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J.
- Venue
- Molecular Psychiatry
- Published
- 2004-03-23
- Volume
- 9
- Issue
- 5
- Pages
- 442-473
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2001657113
- Cited by
- 724
- References
- 247
- FWCI
- 37.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.